Prohibition Partners is set to launch the 10th edition of its leading European Cannabis Report in April 2025, introducing a new interactive digital knowledge hub. This overhaul comes as the cannabis industry experiences significant changes, making it essential for stakeholders to access up-to-date information.
The new digital hub will provide the same in-depth analysis that readers expect, but in a more user-friendly and continuously updated format. This transition reflects the industry’s evolving regulatory landscape, allowing businesses, patients, and stakeholders to gain insights into 31 critical cannabis markets worldwide.
The interactive platform will feature real-time data visualizations, interactive maps, and insights on regulations, pricing, domestic production, and trade. These features are built from comprehensive datasets that Prohibition Partners has been compiling since 2017.
Prohibition Partners CEO, Stephen Murphy, emphasized the need for this update, stating that the company has been tracking the evolution of cannabis markets in Europe since 2017. He noted that this new hub is not just an update but a complete reimagining of how data and insights are delivered to those navigating a rapidly changing industry.
The digital hub will also provide detailed insights into individual markets that are leading cannabis reform efforts. In Germany, recent legislation passed in April 2024 has transformed the medical cannabis market and spurred the formation of cultivation associations for adult-use cannabis. However, uncertainty surrounds the future of adult-use pilot programs due to a shift in government leadership to the conservative CDU/CSU party.
In the Netherlands, a significant adult-use cannabis trial is set to begin on April 7, 2025. Ten municipalities, with a combined population of over 1.6 million, will allow coffee shops to sell cannabis sourced exclusively from licensed suppliers, marking a historic evolution in the country’s drug policy.
Switzerland is already conducting seven adult-use cannabis trials, with initial results showing promise. The Swiss National Council has also moved to draft legislation for the full legalization of adult-use cannabis, with preliminary drafts anticipated soon.
On the medical side, the UK is seeing a steady increase in cannabis import volumes, which have doubled year-on-year. The first UK-produced medical cannabis products are entering the market, indicating growth in patient interest and clinical adoption. Both Germany and the UK are emerging as key manufacturing centers for medical cannabis extracts in Europe.
